Oksana Koneva

Tyra Biosciences reports initial Phase 2 SURF302 results in dabogratinib bladder cancer trial

Tyra Biosciences reports initial Phase 2 SURF302 results in dabogratinib bladder cancer trial
Tyra Biosciences reveals dabogratinib data

Tyra Biosciences announced the initial Phase 2 results from its SURF302 clinical study, which evaluates dabogratinib for the treatment of bladder cancer.

The company noted that the September 9 update on the ongoing development attracted media attention, with multiple outlets covering the new data and its implications for dabogratinib as a therapeutic option.

Earlier this year, Tyra Biosciences presented research breakthroughs in IR NMIBC bladder cancer care at the IBCG26 Annual Retreat. The company engaged with industry peers during the IBC26 forum, highlighting its clinical focus. Tyra's continued updates reflect ongoing developments in its bladder cancer pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.